{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:54:27Z","timestamp":1763754867647,"version":"3.45.0"},"reference-count":42,"publisher":"Oncology Nursing Society (ONS)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Journal of Oncology Nursing"],"published-print":{"date-parts":[[2010,8,1]]},"DOI":"10.1188\/10.cjon.491-499","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T00:45:40Z","timestamp":1280882740000},"page":"491-499","source":"Crossref","is-referenced-by-count":6,"title":["Management of Patients With Chronic Lymphocytic Leukemia Treated With Lenalidomide"],"prefix":"10.1188","volume":"14","author":[{"given":"Kena C.","family":"Miller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurie","family":"Musial","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Whitworth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asher","family":"Chanan-Khan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1302","published-online":{"date-parts":[[2010,8,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.7326\/0003-4819-129-7-199810010-00010","article-title":"Infections in patients with chronic lymphocytic leukemia treated with fludarabine","volume":"129","author":"E. Anaissie","year":"1998","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"2","article-title":"Lenalidomide therapy is associated with normalization of lymphocyte populations and increase in immunoglobulin levels in elderly patients with chronic lymphocytic leukemia [Abstract 10.31]","volume":"94","author":"X. Badoux","year":"2009","journal-title":"Haematologica"},{"issue":"3","key":"3","article-title":"Experience with lenalidomide as initial treatment of elderly patients with chronic lymphocytic leukaemia [Abstract 10.30]","volume":"94","author":"X. Badoux","year":"2009","journal-title":"Haematologica"},{"key":"4","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","article-title":"A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia","volume":"105","author":"J. Byrd","year":"2005","journal-title":"Blood"},{"key":"5","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia","volume":"101","author":"J. Byrd","year":"2003","journal-title":"Blood"},{"issue":"9583","key":"6","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(07)61125-8","article-title":"Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial","volume":"370","author":"D. Catovsky","year":"2007","journal-title":"Lancet"},{"key":"7","unstructured":"Celgene Corporation. (2009). <i>Revlimid\u00ae (lenalidomide)<\/i> [Prescribing information]. Retrieved from <a target=\"_blank\" href='http:\/\/www.revlimid.com\/pdf\/REVLIMID_PI.pdf'>http:\/\/www.revlimid.com\/pdf\/REVLIMID_PI.pdf<\/a>"},{"key":"8","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1200\/JCO.2005.05.0401","article-title":"Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II study","volume":"24","author":"A. Chanan-Khan","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"9","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1200\/JCO.2007.14.5367","article-title":"Lenalidomide for the treatment of B-cell malignancies","volume":"26","author":"A. Chanan-Khan","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"10","first-page":"728","article-title":"A phase II study of lenalidomide in previously untreated, symptomatic chronic lymphocytic leukemia (CLL) [Abstract 44]","volume":"112","author":"C. Chen","year":"2008","journal-title":"Blood"},{"key":"11","first-page":"263","article-title":"Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia","volume":"7","author":"B. Cheson","year":"2009","journal-title":"Clinical Advances in Hematology and Oncology"},{"key":"12","doi-asserted-by":"publisher","first-page":"2767","DOI":"10.1200\/JCO.2007.15.0177","article-title":"Guidelines for the management of pediatric and adult tumor lysis syndrome: An evidence-based review","volume":"26","author":"B. Coiffier","year":"2008","journal-title":"Journal of Clinical Oncology"},{"key":"13","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401909","article-title":"Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity","volume":"2","author":"L. Corral","year":"1996","journal-title":"Molecular Medicine"},{"key":"14","doi-asserted-by":"crossref","unstructured":"Dearden, C. (2008). Disease-specific complications of chronic lymphocytic leukemia. Retrieved from <a target=\"_blank\" href='http:\/\/asheducationbook.hematologylibrary.org\/cgi\/reprint\/2008\/1\/450'>http:\/\/asheducationbook.hematologylibrary.org\/cgi\/reprint\/2008\/1\/450<\/a>","DOI":"10.1182\/asheducation-2008.1.450"},{"key":"15","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"M. Dimopoulos","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"16","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"B. Eichhorst","year":"2006","journal-title":"Blood"},{"key":"17","doi-asserted-by":"publisher","first-page":"5291","DOI":"10.1182\/blood-2007-12-130120","article-title":"Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia","volume":"111","author":"A. Ferrajoli","year":"2008","journal-title":"Blood"},{"key":"18","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1200\/JCO.2006.08.0762","article-title":"Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup trial E2997","volume":"25","author":"I. Flinn","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"19","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s00277-008-0449-0","article-title":"Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes","volume":"87","author":"A. Giagounidis","year":"2008","journal-title":"Annals of Hematology"},{"key":"20","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia","volume":"111","author":"M. Hallek","year":"2008","journal-title":"Blood"},{"key":"21","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3322\/caac.20006","article-title":"Cancer statistics, 2009","volume":"59","author":"A. Jemal","year":"2009","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"22","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2005.12.051","article-title":"Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia","volume":"23","author":"M. Keating","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"23","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion","volume":"355","author":"A. List","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"24","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1080\/10428190600799631","article-title":"Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism","volume":"47","author":"K. Miller","year":"2006","journal-title":"Leukemia and Lymphoma"},{"key":"25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/S0960-894X(99)00250-4","article-title":"Amino-substituted thalidomide analogs: Potent inhibitors of TNF-alpha production","volume":"9","author":"G. Muller","year":"1999","journal-title":"Bioorganic and Medicinal Chemistry Letters"},{"key":"26","unstructured":"National Comprehensive Cancer Network. (2008). <i>NCCN Clinical Practice Guidelines in Oncology\u2122: Non-Hodgkin's lymphoma<\/i> [v.1.2008]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"27","unstructured":"National Comprehensive Cancer Network. (2009). <i>NCCN Clinical Practice Guidelines in Oncology\u2122: Venous thromboembolic disease<\/i> [v.1.2009]. Retrieved from <a target=\"_blank\" href='http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp'>http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp<\/a>"},{"key":"28","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"A. Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"29","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/cncr.0680","article-title":"Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population","volume":"94","author":"J. Perkins","year":"2002","journal-title":"Cancer"},{"key":"30","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","article-title":"Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia","volume":"343","author":"K. Rai","year":"2000","journal-title":"New England Journal of Medicine"},{"key":"31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/j.1365-2354.2004.00489.x","article-title":"The clinical and epidemiological burden of chronic lymphocytic leukaemia","volume":"13","author":"A. Redaelli","year":"2004","journal-title":"European Journal of Cancer Care"},{"key":"32","unstructured":"Robak, T., Moiseev, S. I., Dmoszynska, A., Solal-C\u00e9ligny, P., Warzocha, K., Loscertales, J., \u2026 Wenger, M. K. (2008). Rituximab, fludarabine, and cyclophosphamide (R-FC) prolongs progression-free survival in relapsed or refractory chronic lymphocytic leukemia (CLL) compared with FC alone [Abstract 1]. Retrieved from <a target=\"_blank\" href='http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/ashmtg;112\/11\/lba-1'>http:\/\/abstracts.hematologylibrary.org\/cgi\/content\/abstract\/ashmtg;112\/11\/lba-1<\/a>"},{"issue":"3, Suppl.","key":"33","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1188\/08.CJON. S1.21-27","article-title":"Thromboembolic events associated with novel therapies in patients with multiple myeloma: Consensus statement of the IMF Nurse Leadership Board","volume":"12","author":"S. Rome","year":"2008","journal-title":"Clinical Journal of Oncology Nursing"},{"issue":"2","key":"34","first-page":"373","article-title":"Lenalidomide associated tumor flare reaction correlates with clinical response in patients with relapsed or refractory B-cell chronic lymphocytic leukemia [Abstract 0928]","volume":"94","author":"T. Sher","year":"2009","journal-title":"Haematologica"},{"key":"35","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","article-title":"Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy","volume":"10","author":"I. Sturm","year":"2003","journal-title":"Cell Death and Differentiation"},{"key":"36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"C. Tam","year":"2008","journal-title":"Blood"},{"key":"37","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1002\/cncr.20615","article-title":"A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies","volume":"101","author":"C. Tam","year":"2004","journal-title":"Cancer"},{"key":"38","unstructured":"U. S. Food and Drug Administration. (2005). FDA approves new treatment for myelodysplastic syndrome (MDS). Retrieved from <a target=\"_blank\" href='http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2005\/ucm108546.htm'>http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2005\/ucm108546.htm<\/a>"},{"key":"39","unstructured":"U. S. Food and Drug Administration. (2006). FDA approves lenalidomide oral capsules (Revlimid) for use in combination with dexamethasone in patients with multiple myeloma. Retrieved from <a target=\"_blank\" href='http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm095626.htm'>http:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/CDER\/ucm095626.htm<\/a>"},{"key":"40","unstructured":"U. S. Food and Drug Administration. (2009). FDA approves new treatment for chronic lymphocytic leukemia. Retrieved from <a target=\"_blank\" href='http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm187966.htm'>http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm187966.htm<\/a>"},{"issue":"2","key":"41","first-page":"371","article-title":"A phase I dose-escalation of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia [Abstract 0924]","volume":"94","author":"C. Wendtner","year":"2009","journal-title":"Haematologica"},{"key":"42","doi-asserted-by":"publisher","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"W. Wierda","year":"2005","journal-title":"Journal of Clinical Oncology"}],"container-title":["Clinical Journal of Oncology Nursing"],"original-title":[],"link":[{"URL":"http:\/\/ons.metapress.com\/index\/PH10R84W08332413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T19:49:18Z","timestamp":1763754558000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ons.org\/publications-research\/cjon\/14\/4\/management-patients-chronic-lymphocytic-leukemia-treated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8,1]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,8,1]]}},"alternative-id":["PH10R84W08332413"],"URL":"https:\/\/doi.org\/10.1188\/10.cjon.491-499","relation":{},"ISSN":["1092-1095","1538-067X"],"issn-type":[{"type":"print","value":"1092-1095"},{"type":"electronic","value":"1538-067X"}],"subject":[],"published":{"date-parts":[[2010,8,1]]}}}